Cardiotoxicity and pharmacogenetics of doxorubicin in black Zimbabwean breast cancer patients.

Autor: Nyangwara VA; African Institute of Biomedical Science and Technology, Harare, Zimbabwe.; Department of Biotechnology, Chinhoyi University of Technology, Chinhoyi, Zimbabwe., Mazhindu T; African Institute of Biomedical Science and Technology, Harare, Zimbabwe.; Unit of Internal Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe., Chikwambi Z; African Institute of Biomedical Science and Technology, Harare, Zimbabwe.; Department of Biotechnology, Chinhoyi University of Technology, Chinhoyi, Zimbabwe., Masimirembwa C; African Institute of Biomedical Science and Technology, Harare, Zimbabwe., Campbell TB; Division of Infectious Diseases, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA., Borok M; Unit of Internal Medicine, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe., Ndlovu N; Department of Oncology, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Jazyk: angličtina
Zdroj: British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Aug; Vol. 90 (8), pp. 1782-1789. Date of Electronic Publication: 2023 Jan 27.
DOI: 10.1111/bcp.15659
Abstrakt: Aims: Doxorubicin-induced cardiotoxicity (DIC) is a significant cause of mortality in cancer care. This study was conducted to establish the frequency of DIC in Zimbabwean breast cancer patients on doxorubicin and to test the DIC predictive power of genetic biomarkers.
Methods: A cohort of 50 Zimbabwean breast cancer patients treated with doxorubicin were followed up for 12 months with serial echocardiography and genotyped for UGTA1A6*4, SLC28A3 and RARG. Eleven per cent of the patients experienced DIC.
Results: The frequencies of SLC28A3 (rs7853758), UGT1A6*4 (rs17863783) and RARG (rs2229774) were 60.7%, 17.9% and 14.3%, respectively. No association between DIC and the three variants was observed.
Conclusions: This is the first study on the prevalence of DIC and associated genetic biomarker predictive evaluation in Zimbabwean breast cancer patients. The genetic frequencies observed in our study were different to those reported in other populations. A larger sample size with a longer follow-up time will be necessary in future studies.
(© 2023 British Pharmacological Society.)
Databáze: MEDLINE
Externí odkaz: